Format

Send to

Choose Destination
Expert Opin Ther Targets. 2011 Aug;15(8):961-72. doi: 10.1517/14728222.2011.581232. Epub 2011 May 11.

Targeting miR-375 in gastric cancer.

Author information

1
Zhejiang University School of Medicine, Department of Cell Biology, Program in Molecular Cell Biology, Hangzhou, China.

Abstract

INTRODUCTION:

Gastric cancer remains a major cancer burden in the world, with a poor 5-year survival rate. It is necessary to develop new effective therapeutic strategies to improve the long-term clinical outcome. MicroRNA (miRNA), a class of small non-coding RNA, has been identified as a key regulator of gene expression, and is implicated in the pathogenesis of gastric cancer.

AREAS COVERED:

This review summarizes the role of miRNAs in gastric carcinogenesis, with an emphasis on the expression and function of miR-375 in gastric cancer and beyond. It also discusses the opportunities and challenges of miR-375 as a potential therapeutic target for gastric cancer. The genes targeted by miR-375, including JAK2 and 3'-phosphoinositide dependent protein kinase-1 (PDK1), are also candidates for gastric cancer therapy.

EXPERT OPINION:

Although radical surgery and rational chemotherapy are still the main treatment for gastric cancer, targeting miRNAs, in combination with other conventional therapies, may serve as a promising therapy strategy to improve the clinical outcome.

PMID:
21557705
DOI:
10.1517/14728222.2011.581232
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center